RxDoctor Payments Data

Mary King, DO

Internal Medicine · Largo, FLNPI 1255338083

Payments from drug & device makers

$934in general payments, 2019–2025

Across 50 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$196
  • Amarin Pharma, Inc.$183
  • AstraZeneca$133
  • GSK$123
  • Lilly USA, LLC$75
  • Johnson & Johnson$69
  • plus $155 from 7 others

What the payments were for

  • Food & beverage$934100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$934 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$24,979
Medicare patients
110
Services billed
316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$96,127
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$68,587
TrulicityDulaglutide37$59,473
JardianceEmpagliflozin29$49,116
JanuviaSitagliptin Phosphate20$33,005
FarxigaDapagliflozin Propanediol19$28,442
XareltoRivaroxaban21$26,161
LinzessLinaclotide16$16,287
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$10,444
MyrbetriqMirabegron16$9,828
SymbicortBudesonide/Formoterol Fumarate23$9,384
Albuterol Sulfate HfaAlbuterol Sulfate172$7,894
Fluticasone-SalmeterolFluticasone Propion/Salmeterol38$6,292
Dabigatran EtexilateDabigatran Etexilate Mesylate21$6,087
Atorvastatin Calcium773$5,450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$96,12785 claims
GSKTrelegy Ellipta$123$68,58764 claims
Lilly USA, LLCTrulicity$75$59,47337 claims
AstraZenecaFarxiga, Symbicort$133$37,82642 claims
MerckJanuvia$11$33,00520 claims
Johnson & JohnsonXarelto$69$26,16121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →